NICE backs Grifols' Tavlesse for ITP

19 October 2022

Spanish plasma-derived medicines company Grifols (GRF: MC) today announced that its drug Tavlesse (fostamatinib) has a been recommended by UK health technology assessor the National Institute for Health and Care Excellence (NICE) to treat chronic immune thrombocytopenia (ITP) in adult patients refractory to other treatments.

Investors seemed not to be interested, sending the firm’s shares down 2% to 8.46 euros by midday. The drug has been market in European countries since 2020 and it also commercially available in the USA under the brand name Tavalisse.

With the NICE’s recommendation, specifically for those patients who have previously had a thrombopoietin receptor agonist (TPO-RA), or for whom a TPO-RA is unsuitable, Tavlesse can now be accessed and reimbursed by the National Health Service across all the UK. Last year the Scottish Medicines Consortium advised acceptance of the treatment.3

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK